Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …

Recent advances in the treatment of multiple myeloma have increased the need for accurate
diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Multiple myeloma (MM) is a clonal plasma cell disorder marked by the production of
monoclonal immunoglobulins, leading to various end-organ damages including …

Summary This International Myeloma Working Group consensus updates the disease
definition of multiple myeloma to include validated biomarkers in addition to existing …

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and
SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma …

The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade. The disease definition has been updated to include highly specific biomarkers in …

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …